dual-diagnosis | CARLAT PUBLISHING

Real-World Alcohol Use Disorder Treatment

March 1, 2022

Ismene Petrakis, MD

Addiction psychiatrist and professor at Yale School of Medicine. Chief of Mental Health, VA Connecticut Healthcare System, New Haven, CT.

Dr. Petrakis has disclosed that she participated in a study in which she did not receive any compensation from Alkermes apart from medication and Alkermes did not fund the study. Dr. Capurso has reviewed this material and found no evidence of bias pertaining to this educational activity.

Many patient with alcohol use disorder (AUD) also have comorbid psychiatric illness. Treating these patients can be challenging however there are evidenced based approaches that have been shown to be effective. Dr. Petrakis reviews the latest evidence in treating AUD in this challenging population.

Exposure Therapy Efficacious for PTSD Co-Occurring With Alcohol Use Disorder

November 22, 2019

Brian Frankel, MD

Brian Frankel, MD Dr. Frankel has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Prolonged exposure is one of the best treatments available for patients with PTSD. This study examines the advantages of using prolonged exposure for patients who have PTSD with co-occurring alcohol use disorder.

Varenicline and Bupropion: Soaring Again With EAGLES?

November 22, 2019

Nicholas Rosenlicht, MD.

Nicholas Rosenlicht, MD. Dr. Rosenlicht has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

This research update unpacks the details behind the landmark “EAGLES” trial (Evaluating Adverse Events in a Global Smoking Cessation Study), which led to the removal of the varenicline black box warning.

Can Buprenorphine Improve PTSD Symptoms?

August 1, 2019

Thomas Jordan, MD

Thomas Jordan, MD Dr. Jordan has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

This 2019 retrospective study examines the potential benefits of using buprenorphine/naloxone to treat co-occurring PTSD and opioid use disorder.